Mewburn Ellis has unparalleled experience with SPCs and other Patent Term Extensions (PTEs). We handled the UK’s first SPC application for leuprorelin back in 1993 and we’ve been in the top three firms for SPC filings in recent years, supporting some of the biggest multinational pharma firms worldwide.

Our Speciality Pharma Team regularly supports large and small clients with their extensions strategies and filings. Before filing SPC applications for a medicinal product there should often be a phase of careful strategic analysis to inform the final key decisions about which patent to extend in each country. To conduct this assessment properly, there often needs to be a detailed appreciation of the regulatory picture surrounding a given drug product, and how it might evolve in the future, to be sure of reaching the right decisions. Specialist understanding is important at this stage to avoid missing critical details and going down the wrong path on such a commercially important decision.

Our Speciality Pharma team includes experienced IP counsel who previously specialised in this area while working in-house for a global pharmaceutical company and our team regularly supports clients with such analysis, before progressing to the SPC and PTE filings themselves.

In other situations, our team has assisted with evaluations and due diligences, to understand the likely timelines of exclusivity around a medicinal product in key countries towards a commercial assessment of the asset.

We encourage pharma and life science companies to work with us from an early stage in order that significant opportunities are not missed in maximising extensions and the overall value of a new medicinal product.

Mewburn Ellis have been involved with key aspects of over 1000 SPCs/PTEs for our clients and we’re well-placed to support you in this specialist area of great commercial importance.

Read our Supplementary Protection Certificates (SPCs) & Patent Term Extensions (PTEs) law and practice guide.

Read more about our expertise in the Pharma & Biologics and Speciality Pharma fields.

Meet our SPC & PTE specialists

Sam Bailey Feb-21

Partner, Patent Attorney

Rhiannon Wescott Feb-21

IP Director, Patent Attorney

Andrew Williams - Oct 2022

Partner, Patent Attorney

Thomas Wolter

Partner, Patent Attorney

Sean Jauss Feb-21

Partner, Solicitor, Litigator


Latest News & Insights

SPC Report

Special Report

Pharma and Life Sciences Patent Extensions in Europe

Having compiled and analysed real-world data, this Special Report sets out to provide valuable insights into the following questions that may face decision-makers handling SPC protection for a new drug:

  1. What do the headline SPC statistics tell us?
  2. How to approach the decision of which patent to extend?
  3. What forms of medical technology are being protected by SPCs?
  4. What SPC periods are typically obtained?
  5. How do SPC periods vary with technology type?
  6. How do SPC periods overlay with regulatory protection?
  7. What commercial value can arise from SPCs?